Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
2 ways you can conserve the water used to make your food - 2Virtual reality opens doors for older people to build closer connections in real life
- 3‘More should be done’: UN pushes Syrian regime on justice for Druze, Alawites and minority groups
- 4Building an Individual Brand: Illustrations from Forces to be reckoned with
- 5King Charles shares cancer treatment update, says it's a 'personal blessing'
- 5 Cell phones of the Year
- Artemis moon mission breaks record for distance from Earth
- Best Streaming Gadget for Your Home Theater
- Well known SUVs With Low Energy Utilization In 2024
- 7 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
- Vote In favor of Your Favored Web based Dating Application
- The most effective method to Comprehend the Variables Affecting Medical attendant Pay rates
- Russia patents space station designed to generate artificial gravity
